A5033556560- Endometrial and Cervical Cancer Treatments
- Ovarian cancer diagnosis and treatment
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Prostate Cancer Treatment and Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cervical Cancer and HPV Research
- Lung Cancer Treatments and Mutations
- Lymphoma Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Metastasis and carcinoma case studies
- Cancer Genomics and Diagnostics
- Renal cell carcinoma treatment
- Lung Cancer Research Studies
- Cancer Diagnosis and Treatment
- Inflammatory Biomarkers in Disease Prognosis
- Bladder and Urothelial Cancer Treatments
- Pancreatic and Hepatic Oncology Research
- Neuroendocrine Tumor Research Advances
- Colorectal and Anal Carcinomas
- Lung Cancer Diagnosis and Treatment
- Gastrointestinal Tumor Research and Treatment
- Cancer, Lipids, and Metabolism
- Turkish Literature and Culture
Başkent University
2016-2025
State Hospital
2025
Kırklareli University
2025
Jefferson Healthcare
2025
St. Johns Hospital
2025
Albyn Hospital
2025
St John's Hospital
2025
Başkent University Hospital
2019-2023
Acıbadem Adana Hospital
2022
Kahramanmaraş Sütçü İmam University
2022
PURPOSE Tissue factor is highly expressed in cervical carcinoma and can be targeted by tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study evaluated TV combination with bevacizumab, pembrolizumab, or carboplatin for recurrent metastatic cancer (r/mCC). METHODS open-label, multicenter (ClinicalTrials.gov identifier: NCT03786081 ) included dose-escalation arms that assessed dose-limiting toxicities (DLTs) identified the recommended II dose (RP2D) of bevacizumab (arm A),...
This study evaluates treatment outcomes and possible prognostic factors of inoperable cervical cancer patients treated with external beam radiotherapy (EBRT) high-dose rate brachytherapy (HDR BRT). Between 1993 2000, 183 were at our institute. Radiotherapy was the sole modality until January 1997; after announcement National Cancer Institute in 1999, 40 mg/m(2) cisplatin (49%) routinely applied every week. Median age 54 years (32-92 years). Most (88%) had advanced-stage disease (IIB-IIIB)....
Introduction: This study compares the period during which thromboembolic disease develops after contact with virus before, during, and pandemic. Methods: In this study, medical records of patients a preliminary diagnosis myocardial infarction (MI), pulmonary embolism (PE), ischemic stroke who presented to Emergency Department pandemic (when vaccination rates increased) were retrospectively examined. Data on whether these had COVID-19 or vaccinated, time interval between infection/vaccination...
Importance Clinical trials are vital for advancing cancer treatments and improving patient outcomes. Understanding the factors that influence participants’ decision-making is critical enhancing trial recruitment. Objective To evaluate attitudes of patients with their relatives toward clinical participation, identifying key barriers motivators affect willingness to engage in such trials. Design, Setting, Participants This cross-sectional survey study was conducted between April 2020 2021....
708 Background: This study evaluates the real-world efficacy and safety of avelumab maintenance therapy in metastatic urothelial carcinoma (mUC) patients who have not progressed following first-line platinum chemotherapy, using data from EAP. Methods: The primary endpoint was overall survival (OS), progression-free (PFS) secondary endpoints included safety. PFS OS were estimated by Kaplan-Meier method. Results: One hundred seventeen received at least one cycle Avelumab. median number...
Metastasis-directed therapy (MDT) utilizing stereotactic body radiotherapy (SBRT) for oligoprogressive lesions could provide a delay in next-line systemic treatment (NEST) change while undergoing androgen receptor-targeted agents (ARTA) treatment. We evaluated prognostic factors prostate cancer-specific survival (PCSS) and progression-free (PFS) to characterize patients receiving with ARTA who may benefit from MDT lesions. The impact of on delaying NEST the predictive NEST-free (NEST-FS)...
Based on the CheckMate 649 trial, nivolumab plus chemotherapy is recommended first-line treatment for HER2-negative unresectable advanced or metastatic gastric, gastroesophageal junction (GEJ), esophageal adenocarcinoma. This nationwide, multicenter, retrospective study evaluated real-world effectiveness of this regimen in Turkish patients and identified subgroups that may experience superior outcomes. Conducted across 16 oncology centers Turkey, retrospectively reviewed clinical charts...
:Antifungal effects of plant essential oils (Origanum onites L., Thymbra spicata Lavandula stoechas L. subsp. Foeniculum vulgare Mill. and Laurus nobilis L.) were investigated in vitro conditions against post-harvest fungal pathogen Citrus, Alternaria alternata. O. T. exhibited the strongest antifungal activity A. alternata by inhibiting completely mycelial growth A.alternata at 20.0 80.0 µg ml-1 concentrations, respectively. Conidial germination germ tube elongation was also inhibited...
The objective of this study was to analyze the efficacy and morbidity vaginal cuff brachytherapy alone in intermediate- high-risk stage I endometrial cancer patients after complete surgical staging. Between October 1994 November 2005, 128 with adenocarcinoma were treated high dose rate (HDR) group defined as any grade 3 histology or IB 2 IC disease. comprehensive surgery form total abdominal hysterectomy, bilateral salpingo-oophorectomy addition infracolic omentectomy, routine pelvic...
Background: Although secondary renal involvement from systemic lymphoma is very frequent, primary a rare entity. It characterized by aggressive histopathology, early extra-renal infiltration and poor prognosis. Case Reports: Here, we report 4 cases of presenting with unilateral masses, which after radiological clinical examination were assumed to be cell carcinoma. 3 patients diagnosed Non-Hodgkin's nephrectomy one patient was open biopsy. Histopathological subtypes diffuse large B in 2...
Cisplatin-paclitaxel and bevacizumab is a frequently used treatment regimen for metastatic or recurrent cervical cancer, carboplatin-paclitaxel are also among the recommended regimens. In this study we aimed to evaluate efficacy of these two regimens cancer.Patients with cancer treated cisplatin-paclitaxel were retrospectively evaluated in study. The clinical demographic characteristics patients each group evaluated. Median overall survival, progression-free response rates between groups...
The prognosis of patients with advanced HCC can vary widely depending on factors such as the stage cancer, patient's overall health, and treatment regimens. This study aimed to investigate survival outcomes associated in hepatocellular carcinoma (HCC). In this retrospective study, data from 23 medical oncology clinics were analyzed. Progression-free (PFS) (OS) values estimated using Kaplan–Meier method. Prognostic which identified univariate analysis subsequently evaluated a multivariate...
148 Background: More efficacious treatment options are needed to extend survival and disease control for pts with mCRPC whose progressed after docetaxel. The PD-1 inhibitor pembro has shown manageable safety limited antitumor activity in mCRPC. Preclinical evidence suggests the VEGF/TKI lenva inhibits angiogenesis cell proliferation prostate cancer. In cohort E of phase 1b/2 KEYNOTE-365 study (NCT02861573), efficacy + was evaluated docetaxel-pretreated Methods: Eligible were aged ≥18 years...
Abstract Background Immunotherapy-based combinations have emerged as standard therapies for patients with metastatic renal cell carcinoma (mRCC). Pembrolizumab, a PD-1 inhibitor, combined epacadostat, an indoleamine 2,3-deoxygenase 1 selective demonstrated promising antitumor activity in phase study advanced solid tumors, including mRCC. Methods KEYNOTE-679/ECHO-302 was randomized, open-label, parallel-group, multicenter, 3 (NCT03260894) that compared pembrolizumab plus epacadostat sunitinib...
e16001 Background: Majority of patients with head and neck cancer present locally advanced disease. Most the are treated concurrent chemoradiotherapy. However, toxicities substantial can be associated severe local systemic toxicities. Alternate schedules cisplatin have been tried to overcome these No formal comparison, however, has reported between alternate reference regimen in literature. The primary aim is report a retrospective study comparing schedule standard three weekly bolus terms...